4D Molecular Therapeutics entered a strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region, receiving $85 million upfront and $50 million from cost sharing. Positive long-term safety and efficacy data from the Phase 1/2 PRISM trial in wet AMD was announced. An equity offering provided net proceeds of ~$93 million. The company also completed an equity investment of up to $11 million from the Cystic Fibrosis Foundation for 4D-710 development. With $372 million in cash, cash equivalents, and securities, the company expects to fund operations into the second half of 2028.
In Q3 2025, 4D Molecular Therapeutics reported financial results and operational highlights, emphasizing progress with 4D-150 and 4D-710. Recent corporate highlights include an exclusive license agreement with Otsuka, an equity offering, and the strengthening of the leadership team. The company also created a Retina Leadership Advisory Board. Milestones for 4D-150 include ongoing Phase 3 trials in wet AMD and diabetic macular edema.
4D-150 has shown positive results in wet AMD with the 4FRONT Global Phase 3 Program and PRISM Phase 1/2 Clinical Trial. The therapy has maintained visual acuity, controlled retinal anatomy, and reduced treatment burden. In DME, the SPECTRA Clinical Trial demonstrated strong clinical activity, with a reduction in injection burden. The Phase 3 dose showed promising results compared to lower doses.
In the 4D-710 program for Cystic Fibrosis (CF) Lung Disease, the company secured an equity investment from the CF Foundation to accelerate development. Interim safety and efficacy data from the AEROW Phase 1 clinical trial is expected by the end of 2025. Financially, 4D Molecular Therapeutics had $372 million in cash, cash equivalents, and marketable securities as of September 30, 2025, with net proceeds from the equity offering expected to fund operations into the second half of 2028.
Read more at GlobeNewswire: 4DMT Reports Third Quarter 2025 Financial Results,